Skip to content

Evaluation of the effectiveness of pulmonary rehabilitation on cardiopulmonary parameters and quality of life in patients with scleroderma with pulmonary involvement

Evaluation of the effectiveness of eight weeks of pulmonary rehabilitation on cardiopulmonary parameters and quality of life in patients with scleroderma with pulmonary involvement

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151126025252N1
Enrollment
60
Registered
2022-05-11
Start date
2021-12-22
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Scleroderma. Systemic sclerosis with lung involvement

Interventions

Intervention 1: Intervention Group: Half of the patients with scleroderma with pulmonary involvement in the study undergo CPET and VO2MAX are measured and then, in addition to routine treatments, unde

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with scleroderma according to the 2013 Eular criteria FVC less than 80 percent or CT involvement more than 10 percent No change in the medications taken by patients during the last 3 months These patients should have the ability to do exercise in the hospital and at home

Exclusion criteria

Exclusion criteria: Overlap syndrome and MCTD Inability to perform exercise Contraindications to CPET include:1) Unstable angina, 2) Uncontrolled arrhythmia, 3) Severe aortic stenosis,4) Arterial oxygen with pulse oximetry less than 85% in room air,5) Severe untreated arterial hypertension at rest (SBP200mmHg) (DBP120mmmHg ), 6) Hypertrophic cardiomyopathy 7) Significant orthopedic disorder, 8) Mental disorder,9) Clinical signs of heart failure (pulmonary or peripheral edema) or EF less than 50%, 10) Severe valvular heart disease,11) Pulmonary hypertension >50 mmHg, 12) Acute pulmonary embolism - 13) Sinus tachycardia more than 120,14) Pericarditis, 15) Acute myocarditis, 16) Uncompensated heart failure, 17) Acute systemic disease or fever, 18 ) Coronary disease in the last 4 weeks -19) Metabolic disease such as acute thyroiditis

Design outcomes

Primary

MeasureTime frame
Shortness of breath. Timepoint: The beginning of the study before the intervention and after 8 weeks. Method of measurement: based on the St. George Questionnaire.;Quality of life. Timepoint: The beginning of the study before the intervention and after 8 weeks. Method of measurement: based on SHAQ questionnaire.;Cardiac output. Timepoint: The beginning of the study before the intervention and after 8 weeks. Method of measurement: based on echocardiography.;TLC: Total lung capacity. Timepoint: The beginning of the study before the intervention and after 8 weeks. Method of measurement: based on spirometry.;VO2MAX: Oxygen consumption. Timepoint: The beginning of the study before the intervention and after 8 weeks. Method of measurement: based on cardiopulmonary exercise test.;FVC: forced Vital capacity. Timepoint: The beginning of the study before the intervention and after 8 weeks. Method of measurement: based on spirometry.

Secondary

MeasureTime frame
Modified Rodnan Skin Score : A standard used to measure the degree of skin involvement, which measures the degree of skin tightness in 17 different areas of the body.. In terms of Thickness, it has four degrees: Normal = 0, Mild = 1, Moderate = 2, Severe = 3. Timepoint: At the beginning of the study (before the intervention) and after 8 weeks (the end of the intervention). Method of measurement: Physical Examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Salehi

Tehran University of Medical Sciences

Salehi.Samira90@yahoo.com+98 21 8822 0067

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026